Space Station Leads to Breakthroughs in Human Health on Earth

23 July 2022

NASA Spotlights Angiex’s Space-Based Cancer Research as a Healthcare Breakthrough

Angiex was featured in a NASA article showcasing how research on the International Space Station (ISS) is driving health innovations on Earth. Angiex’s novel cancer therapy, aimed at disrupting the blood supply to tumors, is undergoing testing in the ISS’s microgravity environment. This unique setting allows scientists to observe endothelial cell behavior in a dormant state, which could provide key insights into the therapy’s safety for healthy blood vessels.

The article highlights how NASA’s support for biotech research in space enables companies like Angiex to push the boundaries of oncology. By leveraging microgravity, Angiex hopes to gather critical data that could enhance the safety and effectiveness of its TM4SF1-targeted therapy for cancer patients. This collaboration with NASA marks an exciting leap forward in using space for groundbreaking health advancements.


About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...